Emerging Drug Developer: Hollis-Eden



Emerging Drug Developer:
Hollis-Eden

For years, Hollis-Eden held out high hopes for Neumune, an experimental therapy for acute radiation syndrome. Expecting a government contract under Project BioShield, the company was stunned by a government decision in March to axe its ARS plans. Scrambling to restructure, Hollis-Eden today is focused on a new lead therapy now in Phase I. 

In the process, Hollis-Eden is rapidly shedding its image as a bioterror company and speeding programs into and through clinical trials. It believes its science can soon pay off with proof-of-concept data for new drugs targeting diabetes as well as rheumatoid arthritis, while its drug platform spawns new preclinical candidates for its pipeline. That government program? Who needs it. Article  -John

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.